Call Options

1 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2017

Nov 14, 2017

BUY
$5.4 - $8.47 $308,880 - $484,484
57,200
57,200 $437,000

Others Institutions Holding IMGN

About ImmunoGen, Inc.


  • Ticker IMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 220,712,992
  • Description
  • ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...
More about IMGN
Track This Portfolio

Track Highbridge Capital Management LLC Portfolio

Follow Highbridge Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Highbridge Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Highbridge Capital Management LLC with notifications on news.